Shanghai Pioneer Holding Gestion
Gestion contrôle des critères 3/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Steven Yang
Directeur général
CN¥655.0k
Rémunération totale
| Pourcentage du salaire du PDG | 78.8% |
| Durée du mandat du directeur général | 1.6yrs |
| Propriété du PDG | n/a |
| Durée moyenne d'occupation des postes de direction | 4.5yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 2.9yrs |
Mises à jour récentes de la gestion
Recent updates
Shareholders Should Be Pleased With Shanghai Pioneer Holding Ltd's (HKG:1345) Price
Jul 15
Shanghai Pioneer Holding's (HKG:1345) Dividend Will Be CN¥0.024
Apr 24Shanghai Pioneer Holding (HKG:1345) Will Pay A Dividend Of CN¥0.024
Apr 03Shanghai Pioneer Holding's (HKG:1345) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 01Shanghai Pioneer Holding Ltd (HKG:1345) Could Be Riskier Than It Looks
Mar 22Shanghai Pioneer Holding (HKG:1345) Is Finding It Tricky To Allocate Its Capital
Feb 26Does Shanghai Pioneer Holding (HKG:1345) Have A Healthy Balance Sheet?
Oct 21Shanghai Pioneer Holding (HKG:1345) Has Announced That It Will Be Increasing Its Dividend To CN¥0.024
Sep 18Shanghai Pioneer Holding (HKG:1345) Is Increasing Its Dividend To CN¥0.024
Sep 01Here's Why We Think Shanghai Pioneer Holding (HKG:1345) Is Well Worth Watching
Aug 09Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Apr 14Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 31Shanghai Pioneer Holding (HKG:1345) Seems To Use Debt Rather Sparingly
Dec 15China Pioneer Pharma Holdings' (HKG:1345) Dividend Will Be Reduced To CN¥0.018
Sep 21China Pioneer Pharma Holdings' (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Sep 02China Pioneer Pharma Holdings (HKG:1345) Has More To Do To Multiply In Value Going Forward
Jun 22China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.064
Apr 14China Pioneer Pharma Holdings (HKG:1345) Will Be Hoping To Turn Its Returns On Capital Around
Jan 16These 4 Measures Indicate That China Pioneer Pharma Holdings (HKG:1345) Is Using Debt Safely
Oct 11China Pioneer Pharma Holdings (HKG:1345) Is Paying Out Less In Dividends Than Last Year
Sep 15China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.056
Sep 01China Pioneer Pharma Holdings (HKG:1345) Will Be Looking To Turn Around Its Returns
Aug 26Returns On Capital At China Pioneer Pharma Holdings (HKG:1345) Paint A Concerning Picture
May 22We Think China Pioneer Pharma Holdings (HKG:1345) Can Stay On Top Of Its Debt
Apr 25Can Mixed Financials Have A Negative Impact on China Pioneer Pharma Holdings Limited's 's (HKG:1345) Current Price Momentum?
Mar 14How Has China Pioneer Pharma Holdings (HKG:1345) Allocated Its Capital?
Feb 21
Should You Use China Pioneer Pharma Holdings' (HKG:1345) Statutory Earnings To Analyse It?
Feb 03Is China Pioneer Pharma Holdings Limited (HKG:1345) At Risk Of Cutting Its Dividend?
Jan 16China Pioneer Pharma Holdings (HKG:1345) Has A Rock Solid Balance Sheet
Dec 29Is China Pioneer Pharma Holdings Limited's (HKG:1345) Stock Price Struggling As A Result Of Its Mixed Financials?
Dec 14China Pioneer Pharma Holdings (HKG:1345) Has Gifted Shareholders With A Fantastic 124% Total Return On Their Investment
Nov 29Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥164m |
| Mar 31 2024 | n/a | n/a | CN¥155m |
| Dec 31 2023 | CN¥655k | CN¥516k | CN¥146m |
| Sep 30 2023 | n/a | n/a | CN¥168m |
| Jun 30 2023 | n/a | n/a | CN¥190m |
| Mar 31 2023 | n/a | n/a | CN¥213m |
| Dec 31 2022 | CN¥752k | CN¥624k | CN¥235m |
Rémunération vs marché: La rémunération totale de Steven ($USD 90.37K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 390.12K ).
Rémunération et revenus: La rémunération de Steven a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Steven Yang (36 yo)
1.6yrs
Titularisation
CN¥655,000
Compensation
Mr. Yuewen Yang, also known as Steven, serves as Chief Executive Officer since April 2023 and serves as its Executive Director since September 16, 2022 and served as Chief Operating Officer at Shanghai Pio...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chairman | 11.8yrs | CN¥2.05m | 0.95% HK$ 23.3m | |
| CEO & Executive Director | 1.6yrs | CN¥655.00k | pas de données | |
| General Manager of Dental Business Division & Executive Director | 3.3yrs | CN¥717.00k | pas de données | |
| Chief Financial Officer | 7.9yrs | pas de données | pas de données | |
| General Manager of Investment Unit | no data | pas de données | pas de données | |
| Director of Personnel | no data | pas de données | pas de données | |
| Company Secretary | 5.7yrs | pas de données | pas de données |
4.5yrs
Durée moyenne de l'emploi
49yo
Âge moyen
Gestion expérimentée: L'équipe de direction de 1345 est considérée comme expérimentée (ancienneté moyenne 4.5 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chairman | 11.8yrs | CN¥2.05m | 0.95% HK$ 23.3m | |
| CEO & Executive Director | 2.2yrs | CN¥655.00k | pas de données | |
| General Manager of Dental Business Division & Executive Director | 1.1yrs | CN¥717.00k | pas de données | |
| Independent Non-Executive Director | 2.9yrs | CN¥270.00k | pas de données | |
| Independent Non-Executive Director | 5.8yrs | pas de données | pas de données | |
| Non-Executive Director | 3.9yrs | CN¥184.00k | pas de données | |
| Independent Non-Executive Director | less than a year | pas de données | pas de données |
2.9yrs
Durée moyenne de l'emploi
60yo
Âge moyen
Conseil d'administration expérimenté: Le conseil d'administration de la 1345 n'est pas considéré comme expérimenté ( 2.9 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.